Risk factors for severe immune-related pneumonitis after nivolumab plus ipilimumab therapy for non-small cell lung cancer.
Sumi T, Sekikawa M, Koshino Y, Nagayama D, Nagahisa Y, Matsuura K, Shijubou N, Kamada K, Suzuki K, Ikeda T, Michimata H, Watanabe H, Yamada Y, Osuda K, Tanaka Y, Chiba H.
Sumi T, et al. Among authors: watanabe h.
Thorac Cancer. 2024 Jun 3. doi: 10.1111/1759-7714.15385. Online ahead of print.
Thorac Cancer. 2024.
PMID: 38828610